Pharmacogenomics & Personalized Medicine最新文献

{"title":"miR-139-5p and miR-451a as a Diagnostic Biomarker in LUSC.","authors":"Bo Gao,&nbsp;Rui Li,&nbsp;Xiaojia Song,&nbsp;Shan Hu,&nbsp;Fengmei Yang","doi":"10.2147/PGPM.S402750","DOIUrl":"https://doi.org/10.2147/PGPM.S402750","url":null,"abstract":"<p><strong>Background: </strong>Lung squamous cell carcinoma (LUSC) is a type of lung cancer that originates from segmental or subsegmental bronchial mucosa. There is evidence that miRNA plays an important role in the occurrence and progression of tumors.</p><p><strong>Methods: </strong>In this study, plasma samples of patients with early LUSC and healthy volunteers were subjected to miRNA sequencing, and the levels of differentially expressed miRNAs (DEMs) in LUSC tissues were analyzed using R language. Cox regression and Kaplan-Meier (K-M) survival curve analyses were performed to determine the relationship between DEMs and prognosis in LUSC, and PCR method was verified for the plasma expression level of DEMs in patients with LUSC. The levels of CYFRA21-1 and SCC-Ag in plasma were measured, and area under curve (AUC) was used to evaluate the diagnostic value of the DEMs.</p><p><strong>Results: </strong>A total of 21 DEMs were screened out by sequencing. The expression levels of DEMs in tissue samples in the TCGA database were analyzed, and four DEMs with consistent expression levels were further screened from plasma and tissue samples. Regression analysis and K-M curve were performed to select two DEMs (miR-139-5p, miR-451a) that were correlated with the prognosis. PCR verification results showed that the levels of miR-451a and miR-139-5p were low in patients, and the level of miR-139-5p in late stages III & IV with the patients of LUSC was higher than that in stages I & II. The AUC values of the four indicators (SCC-Ag, CYFRA21-1, miR-451a and miR-139-5p) in the diagnosis of LUSC, early and late cases were 0.884, 0.935 and 0.778, respectively.</p><p><strong>Conclusion: </strong>The detection of miR-139-5p and miR-451a levels in plasma has a certain potential in the non-invasive diagnosis, especially in patients with early stages of LUSC.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/7a/pgpm-16-313.PMC10093518.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9309477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of <i>CYP19A1</i> Loci (rs28757157 and rs3751591) with Ischemic Stroke Risk in the Chinese Han Population.","authors":"Kang Huang,&nbsp;Tianyi Ma,&nbsp;Qiang Li,&nbsp;Zanrui Zhong,&nbsp;Ting Qin,&nbsp;Yilei Zhou,&nbsp;Wei Zhang,&nbsp;Shilin Tang,&nbsp;Jianghua Zhong,&nbsp;Shijuan Lu","doi":"10.2147/PGPM.S404160","DOIUrl":"https://doi.org/10.2147/PGPM.S404160","url":null,"abstract":"<p><strong>Introduction: </strong>Ischemic stroke (IS) is a multifactorial and polygenic disease, which is affected by genetic factors. In this study, we explored the role of <i>CYP19A1</i> single nucleotide polymorphisms (SNPs) in IS in the Chinese population.</p><p><strong>Methods: </strong>1302 subjects (651 controls and 651 cases) were recruited in this case-control study. Four candidate SNPs (rs28757157 C/T, rs3751592 C/T, rs3751591 G/A, rs59429575 C/T) of <i>CYP19A1</i> were selected by the 1000 genomes project database. The association between <i>CYP19A1</i> SNPs and IS risk was assessed using logistic regression analysis with odds ratio (OR) and 95% confidence intervals (CIs). False-positive report probability (FPRP) analysis further verified the positive results. The interaction of SNP-SNP was analyzed by multi-factor dimensionality reduction (MDR) to predict is risk.</p><p><strong>Results: </strong>In the research, <i>CYP19A1</i> loci (rs28757157 and rs3751591) were associated with the occurrence of IS. The two variants conferred an increased susceptibility to IS in the subjects aged over 60 years old, smokers and drinkers. Rs28757157 was related to the risk of IS in females, non-smokers and subjects with BMI less than 24, while rs59429575 was related to the risk of IS in males and subjects with BMI greater than 24.</p><p><strong>Conclusion: </strong>The study revealed that there is a significant association between <i>CYP19A1</i> loci (rs28757157 and rs3751591) and IS risk in the Chinese Han population, providing a theoretical basis for further exploring its specific role in the pathogenesis of IS.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/10/pgpm-16-491.PMC10237203.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9951394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives.","authors":"Judith Wellens,&nbsp;Eva Vissers,&nbsp;Christophe Matthys,&nbsp;Séverine Vermeire,&nbsp;João Sabino","doi":"10.2147/PGPM.S359365","DOIUrl":"https://doi.org/10.2147/PGPM.S359365","url":null,"abstract":"<p><p>Inflammatory bowel diseases (IBD) are chronic and incurable conditions of the gastro-intestinal tract with an increasing incidence and prevalence worldwide. Common symptoms are abdominal pain, diarrhea, and weight loss. Despite recent advances in medical management, many patients fail to achieve clinical remission and healing of the mucosa of the bowel. The cause is thought to involve an inappropriate reaction of the immune system, the microbiome and the environment in genetically susceptible individuals, leading to chronic bowel inflammation. Evidence is emerging that diet is a key environmental factor that might influence disease onset and course, and therefore may become a therapeutic strategy to mitigate inflammation and symptoms. Since IBD is a heterogeneous disease on a clinical and a molecular level, personalizing dietary advice could be the crucial factor to achieve long-lasting changes in dietary behaviors that could not only improve nutritional status but also tackle gut inflammation and abdominal symptoms on an individual level. In this review, we first discuss different aspects of personalized nutrition, namely the level, focus, and scope of personalized dietary regimens. Then, we provide a framework for the different goals of nutritional therapy in IBD and current evidence for personalized dietary approaches. Lastly, we discuss the need for adequate trial designs, access to the right data types and the bioinformatic tools that are necessary to develop algorithms that will allow us to move from general \"healthy eating\" advice to truly personalized nutritional plans for the individual IBD patient.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/ef/pgpm-16-15.PMC9842524.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10554504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma.","authors":"Chunlan Zheng,&nbsp;Yanan Peng,&nbsp;Haizhou Wang,&nbsp;Youwei Wang,&nbsp;Lan Liu,&nbsp;Qiu Zhao","doi":"10.2147/PGPM.S397892","DOIUrl":"https://doi.org/10.2147/PGPM.S397892","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world with an immunosuppressive Tumor microenvironment (TME). Ferroptosis plays an essential role in tumor proliferation, invasion, and metastasis. However, the relationship between ferroptosis and TME of HCC has remained elusive.</p><p><strong>Methods: </strong>Differentially expressed ferroptosis-related genes (DE FRGs) between normal liver tissues and HCC tissues were obtained from The Cancer Genome Atlas (TCGA). On this basis, we identified the molecular subtypes mediated by DE FRGs and TME cell infiltration. Next, a predictive signature was established to quantity the ferroptosis-related characteristics by performing the least absolute shrinkage and selection operator Cox regression analyses. Univariate and multivariate COX analyses determined the independent prognostic factors. Finally, the expression stability of 3 ferroptosis-related signature genes was verified in cancer and paracancerous normal tissues of HCC.</p><p><strong>Results: </strong>We identified three different molecular subtypes and found that the subtype with the better prognosis was associated with high enrichment of immune- and metabolic-related hallmark signaling pathways and high infiltration of immune cells in TME. The signature was considered to be an independent prognostic factor. We also found that the signature can reflect the infiltration characteristics of different immune cells in TME. Immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), regulatory T cells, and type 17 T helper cells were significantly enriched in the high-risk group. The analysis data of immune checkpoints and tumor mutation load indicated that the signature had great potential in predicting Immunotherapy response and chemotherapeutic sensitivity. In addition, the overexpression of 3 ferroptosis-related signature genes was confirmed in HCC tissues and HCC cell lines. Ferroptosis inducer RSL3 inhibited the proliferation of HCC cells and was a potential cancer immunotherapy agent.</p><p><strong>Conclusion: </strong>These findings enhanced our understanding of the regulatory mechanism of ferroptosis in HCC and provided new insights into evaluating prognosis and developing more effective Immunotherapy and chemotherapy strategies.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/be/pgpm-16-39.PMC9885776.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10633234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Two Novel Variants of the <i>DMD</i> Gene in Chinese Families with Duchenne Muscular Dystrophy.","authors":"Jiangfen Wu,&nbsp;Lingyan Ren,&nbsp;Xinyi Huang,&nbsp;Li Hu,&nbsp;Liangliang Zhang,&nbsp;Dan Xie,&nbsp;Zhimin Li,&nbsp;Naijian Han,&nbsp;Shengwen Huang","doi":"10.2147/PGPM.S416294","DOIUrl":"https://doi.org/10.2147/PGPM.S416294","url":null,"abstract":"<p><strong>Background: </strong>Duchenne muscular dystrophy (DMD), an X-linked recessive neuromuscular disorder, is caused by pathogenic variants in the <i>DMD</i> gene encoding a large structural protein in muscle cells.</p><p><strong>Methods: </strong>Two probands, a 6-year old boy and a 1-month old infant, respectively, were clinically diagnosed with DMD based on elevated levels of creatine kinase and creatine kinase isoenzyme. CNVplex and whole exome sequencing (WES) were performed for causal variants, and Sanger sequencing was used for verification.</p><p><strong>Results: </strong>CNVplex found no large deletions or duplications in the <i>DMD</i> gene in both patients, but WES discovered a single-nucleotide deletion in exon 48 (NM_004006.2:c.6963del, p.Asp2322ThrfsTer16) in the proband of pedigree 1, and a nonsense mutation in exon 27 (NM_004006.2:c.3637A>T, p.K1213Ter) in the proband of pedigree 2.</p><p><strong>Conclusion: </strong>The results of our study expand the mutation spectrum of DMD and enrich our understanding of the clinical characteristics of DMD. Genetic counseling was provided for the two families involved in this study.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cc/c8/pgpm-16-759.PMC10441636.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10413897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline <i>PRDM1</i> Variant rs2185379 in Long-Term Recurrence-Free Survivors of Advanced Ovarian Cancer.","authors":"Takashi Mitamura,&nbsp;Tianyue Zhai,&nbsp;Kanako C Hatanaka,&nbsp;Yutaka Hatanaka,&nbsp;Toraji Amano,&nbsp;Lei Wang,&nbsp;Shinya Tanaka,&nbsp;Hidemichi Watari","doi":"10.2147/PGPM.S387120","DOIUrl":"https://doi.org/10.2147/PGPM.S387120","url":null,"abstract":"<p><strong>Purpose: </strong>To identify the germline genetic characteristics of long-term recurrence-free survivors that can be applied to establishing a new strategy for curing advanced cancer, we investigated the whole-genome single nucleotide variants of ovarian cancer patients.</p><p><strong>Patients and methods: </strong>DNA specimens were obtained from rare long-term recurrence-free survivors with FIGO stage III-IV ovarian cancer with no recurrence for 8-23 years after primary treatments for a whole-genome analysis of approximately 660,000 single nucleotide variants. We then established a mouse model with a notable gene alteration by CRISPR/Cas9 to confirm the biological role.</p><p><strong>Results: </strong>The long-term recurrence-free survivors more frequently had germline heterozygous variant rs2185379 of the <i>PRDM1</i> gene exon than patients with early recurrence (6.8-fold, P=0.013) and the general population. In the mouse model, primary intraperitoneal disseminated tumors of allograft ID8 were significantly smaller in the germline heterozygous rs2185379 group than in the wild-type group (57.4% decrease, P=0.008). Immunohistochemistry showed that the area of distribution of infiltrating T lymphocytes with positive CD8 staining was significantly increased in the germline heterozygous rs2185379 group in comparison to the wild-type group.</p><p><strong>Conclusion: </strong>Germline heterozygous rs2185379 in <i>PRDM1</i> is correlated with an excellent prognosis and can be used to establish a new strategy for treating advanced ovarian cancer.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/0a/pgpm-15-977.PMC9719363.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35210812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database.","authors":"Nina L Wittwer,&nbsp;Christoph R Meier,&nbsp;Carola A Huber,&nbsp;Henriette E Meyer Zu Schwabedissen,&nbsp;Samuel Allemann,&nbsp;Cornelia Schneider","doi":"10.2147/PGPM.S382214","DOIUrl":"https://doi.org/10.2147/PGPM.S382214","url":null,"abstract":"<p><strong>Purpose: </strong>In Switzerland 167 drugs on the market contain information about pharmacogenetics in their drug label (PGx drug). Preemptive pharmacogenetic testing is reimbursed by health care insurance for only seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) although, it is proposed to be a cost-effective approach to personalized medicine. The aim of this study was to describe the use of PGx drugs and their corresponding genes in Switzerland.</p><p><strong>Methods: </strong>We identified 90 drugs with dosing recommendations from the Pharmacogenetic Knowledgebase involving 24 genes. We assessed the utilization of those drugs between 2016 and 2020, using claims data from a large Swiss insurance company (Helsana).</p><p><strong>Results: </strong>Of 841 491 persons with drug claims during the whole study period, 78.7% were exposed to PGx drugs. Ibuprofen, pantoprazole, and tramadol had the highest number of users. Seven genes (<i>CYP2C19, CYP2C9, CYP2D6, SLCO1B1, HLA-B, MT-RNR1</i>, and <i>VKORC1</i>) were responsible for over 95% of all potential drug-gene interactions.</p><p><strong>Conclusion: </strong>The prevalence of PGx drug prescriptions is high in the Swiss population. Therefore, intensified preemptive testing may be a useful option as a substantial amount of the Swiss population might benefit.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/dd/pgpm-15-967.PMC9701506.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40723062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders.","authors":"Marta H Hernandez,&nbsp;Valentin Bote,&nbsp;Alexandre Serra-LLovich,&nbsp;Marc Cendros,&nbsp;Juliana Salazar,&nbsp;Conxita Mestres,&nbsp;Silvina Guijarro,&nbsp;Aida Alvarez,&nbsp;Cristina Lamborena,&nbsp;Iria Mendez,&nbsp;Bernardo Sanchez,&nbsp;Amaia Hervas,&nbsp;Maria J Arranz","doi":"10.2147/PGPM.S377210","DOIUrl":"https://doi.org/10.2147/PGPM.S377210","url":null,"abstract":"<p><strong>Purpose: </strong>Autistic spectrum disorders (ASD) children and adolescents usually present comorbidities, with 40-70% of them affected by attention deficit hyperactivity disorders (ADHD). The first option of pharmacological treatment for these patients is methylphenidate (MPH). ASD children present more side effects and poorer responses to MPH than ADHD children. The objective of our study is to identify genetic biomarkers of response to MPH in ASD children and adolescents to improve its efficacy and safety.</p><p><strong>Patients and methods: </strong>A retrospective study with a total of 140 ASD children and adolescents on MPH treatment was included. Fifteen polymorphisms within genes coding for the MPH target NET1 (<i>SLC6A2</i>) and for its primary metabolic pathway (<i>CES1</i>) were genotyped. Multivariate analyses including response phenotypes (efficacy, side-effects, presence of somnolence, irritability, mood alterations, aggressivity, shutdown, other side-effects) were performed for every polymorphism and haplotype.</p><p><strong>Results: </strong>Single marker analyses considering gender, age, and dose as covariates showed association between <i>CES1</i> variants and MPH-induced side effects (rs2244613-G (p=0.04), rs2302722-C (p=0.02), rs2307235-A (p=0.03), and rs8192950-T alleles (p=0.03)), and marginal association between the CES1 rs2302722-C allele and presence of somnolence (p=0.05) and the SLC6A2 rs36029-G allele and shutdown (p=0.05). A CES1 haplotype combination was associated with efficacy and side effects (p=0.02 and 0.03 respectively). SLC6A2 haplotype combination was associated with somnolence (p=0.05).</p><p><strong>Conclusion: </strong>CES1 genetic variants may influence the clinical outcome of MPH treatment in ASD comorbid with ADHD children and adolescents.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/47/pgpm-15-951.PMC9653043.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40694622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-Generation Sequencing and Bioinformatics-Based Protocol for the Full-Length <i>CYP2E1</i> Gene Polymorphism Analysis.","authors":"Viktorija Igumnova,&nbsp;Agnija Kivrane,&nbsp;Anda Viksna,&nbsp;Inga Norvaisa,&nbsp;Renate Ranka","doi":"10.2147/PGPM.S371709","DOIUrl":"https://doi.org/10.2147/PGPM.S371709","url":null,"abstract":"<p><strong>Introduction: </strong>Pharmacogenetics studies provide clinically relevant information on the identified associations between genetic variants and individual variability in drug response, which, in turn, offers great promise for guiding personalized drug therapy and clinical trial design. However, there is a lack of information concerning the evidence-based clinical annotations of specific <i>CYP2E1</i> genetic variants.</p><p><strong>Aim: </strong>To design and evaluate the next-generation sequencing-based method for full-length <i>CYP2E1</i> gene polymorphism analysis.</p><p><strong>Materials and methods: </strong>Seven gene-specific oligonucleotide primer pairs targeting overlapping <i>CYP2E1</i> gene fragments spanning all nine gene exons with interleaving introns, untranslated (UTR) and intergenic regions were designed. Human DNA samples (n = 3) were used as a training set to check the primer performance and to optimize the PCR conditions. The effectiveness of the developed target amplification and sequencing protocol was evaluated using the test set comprising human DNA samples (n = 3) obtained from tuberculosis patients. Sequencing data analysis was performed on the Galaxy online-based platform.</p><p><strong>Results: </strong>The sequencing data quality was sufficient for the detection of genetic variants dispersed throughout the <i>CYP2E1</i> gene with a high degree of confidence in fully covered regions achieving optimal reading depth of the targeted fragment with high base call accuracy.</p><p><strong>Conclusion: </strong>Developed protocol can be applied in subpopulation-level association studies to determine whether single nucleotide variants (SNVs) or variant combinations from multiple regions of the <i>CYP2E1</i> gene are of clinical significance.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/be/pgpm-15-959.PMC9653044.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40710817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilizing Pharmacogenomics Results to Determine Opioid Appropriateness and Improve Pain Management in a Patient with Osteoarthritis.","authors":"Katie Pizzolato,&nbsp;David Thacker,&nbsp;Nicole Marie Del Toro-Pagán,&nbsp;Nishita S Amin,&nbsp;Abeer Hanna,&nbsp;Jacques Turgeon,&nbsp;Veronique Michaud","doi":"10.2147/PGPM.S385272","DOIUrl":"https://doi.org/10.2147/PGPM.S385272","url":null,"abstract":"<p><p>The opioid epidemic in the United States has exposed the need for providers to limit opioid dispensing and identify at-risk patients prior to prescribing opioids. With pharmacogenomic testing, clinicians can analyze hundreds of medications-including commonly prescribed opioids-against genetic results to understand and predict risk and response. Moreover, knowledge of genotypic variants and altered function can help decrease trial and error prescribing, identify patients at-risk for adverse drug events, and improve pain control. This patient case demonstrates how pharmacogenomic test results identified drug-gene interactions and provided insight about a patient's inadequate opioid therapy response. With pharmacogenomic information, the patient's healthcare team discontinued opioid therapy and selected a more appropriate regimen for osteoarthritis (ie, celecoxib), resulting in improved pain control and quality of life.</p>","PeriodicalId":56015,"journal":{"name":"Pharmacogenomics & Personalized Medicine","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2022-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e5/0e/pgpm-15-943.PMC9651068.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40710816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}